Moody's Ratings Downgrades Kenvue Inc. (KVUE) Outlook from "Stable" to "Negative"

Third Point Management holds $178,428,250 worth of Kenvue Inc. (NYSE:KVUE) shares, representing 2.34% of its portfolio. The stock is included in our list of Billionaire Dan Loeb’s 10 Stocks with Huge Upside Potential.

On October 3, 2025, Moody’s Ratings downgraded Kenvue Inc. (NYSE:KVUE)’s outlook from “Stable” to “Negative.”

Moody’s downgrade reflects Kenvue Inc. (NYSE:KVUE)’s ongoing operational headwinds and litigation risks that negatively impacted its earnings and cash flow. At the same time, Moody’s affirmed the company’s A1 long-term issuer and Prime-1 commercial paper ratings. However, the company’s weaker sales trends and cash outflows from restructuring were noted, which could result in negative free cash flow this year.

Meanwhile, Kenvue Inc. (NYSE:KVUE)’s leverage remains on the higher end at 2.8x debt-to-EBITDA, above its 2x target. On the other hand, share repurchases are expected to stay on hold until deleveraging improves. Additionally, legal uncertainty remains as acetaminophen-related lawsuits shift to the U.S. Court of Appeals, with a ruling expected by early 2026.

On the positive side, Moody’s noted Kenvue Inc. (NYSE:KVUE)’s diversified portfolio, stable liquidity, and ongoing strategic review aimed at restoring profitability.

Kenvue Inc. (NYSE:KVUE) is a global consumer health company across the U.S., operating through Self Care, Skin Health & Beauty, and Essential Health segments. It is included in Dan Loeb’s stock portfolio.

While we acknowledge the potential of KVUE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Cheap Clean Energy Stocks to Buy Right Now and 15 Best Robotics Stocks to Buy Under $20.

Disclosure: None.